Alkem Laboratories

Alkem Laboratories Current Liabilities

The Current Liabilities of Alkem Laboratories (ALKEM.NS) as of Oct 21, 2026 is 47.16 B INR. In the previous year, Current Liabilities was 46.99 B INR — a change of 0.36% (higher).

Current Liabilities

47.16 BINR

YoY

0.36%

Last updated:

Current Liabilities of Alkem Laboratories is 2026 47.16 B INR. Current Liabilities of Alkem Laboratories was 2025 46.99 B INR. It decreases by 0.36% higher compared to the previous year.

The Alkem Laboratories Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
24.78 B INR
Jan 1, 2020
36.15 B INR
Jan 1, 2021
33.85 B INR
Jan 1, 2022
53.14 B INR
Jan 1, 2023
43.41 B INR
Jan 1, 2024
45.66 B INR
Jan 1, 2025
46.99 B INR
Jan 1, 2026
47.16 B INR
The Alkem Laboratories Current Liabilities history
YEARCurrent LiabilitiesYoY
47.16 BINR+0.36%
46.99 BINR+2.92%
45.66 BINR+5.18%
43.41 BINR-18.31%
53.14 BINR+56.99%
33.85 BINR-6.35%
36.15 BINR+45.85%
24.78 BINR-10.87%
27.81 BINR+46.66%
18.96 BINR+4.78%
18.09 BINR-19.99%
22.61 BINR+47.72%
15.31 BINR-7.22%
16.50 BINR+40.29%
11.76 BINR+15.15%
10.21 BINR+301.69%
2.54 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alkem Laboratories stock

Current Liabilities of Alkem Laboratories is 47.16 B INR in 2026.

Current Liabilities of Alkem Laboratories changed from 46.99 B INR to 47.16 B INR, representing a 0.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Alkem Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alkem Laboratories

All Key Metrics — Alkem Laboratories